Wang D,Hu B,Hu C,Zhu F,Liu X,Zhang J .2020 .Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323 : 1061-9.
Galib BA .2019 .SARS-CoV-2(COVID-19). J Fac Med Bagdad, 61 : 91-3.
Mahdi BM .2022 .Asthma as a Risk Factor for the Progression of COVID-19. Acta facultatismedicae Naissensis, 39 : 165-172.
Dawood H,Hwayyiz A,Ibrahim I,Abdul Rahman I. .2021 .The clinical features of COVID - 19 in a group of Iraqi patients: A record review. J Fac Med Bagdad, 63 : 8-12.
Mahdi BM .2020 .COVID-19 type III hypersensitivity reaction. Med Hypotheses, 109763 : 109763.
Allawi JS,Abbas HM,Rasheed JI,Sulaiman TI,Gatea AA,Al-Lami F .2020 .The first 40-days experience and clinical outcomes in the management of coronavirus covid-19 crisis. Single center preliminary study. J Fac Med Bagdad, 61 : 94-9.
Mahdi BM .2021 .9(A. Vaccine Hesitancy and Acceptance among Medical Students: An Online Crosssectional Study in Iraq. Maced J Med Sci, : 955-8.
Mahdi BM,Dermo-Sifiliográficas Attitude. Actas .2022 .Contact Dermatitis from Amplified Hand Hygiene Practices In The COVID-19 Pandemic Among Medical Students: Frequency, Knowledge, and. Available online 11 July, : .
Jesenak M,Brndiarova M,Urbancikova I,Rennerova Z,Vojtkova J,Bobcakova A .2020 .Immune parameters and COVID-19 Infection-Associations with clinical severity and disease prognosis. Front Cell Infect Microbiol, 10 : 364.
Holub M,Lawrence DA,Andersen N,Beran A,O A .2013 .Cytokines and chemokines as biomarkers of community-acquired bacterial infection. Mediators Inflamm, : .
Albrich WC,Harbarth S. Pros .2015 .and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Intensive Care Med, 41(10) : 1739-51.
Charles PE,Tinel C,Barbar S,Aho S,Prin S,Doise JM .2009 .Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care, 13 : .
Pink I,Raupach D,Fuge J. .2021 .C-reactive protein and procalcitonin for antimicrobial stewardship in COVID19. Infection, 49 : 935-943.
Lippi G,Plebani M. .2020 .Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta, 505 : 190-1.
Hu R,Han C,Pei S,Yin M,Chen X .2020 .Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents, 10605(2) : 1.
.2020 .State Council of The People's Republic of China. The notice of launching guideline on diagnosis and treatment of the novel coronavirus pneumonia (6th edition. , 54 : 8094.
Gandhi RT,Lynch JB,Del Rio C .2020 .. Mild or Moderate Covid-19.N Engl J Med, 383(18) : 1757-1766.
Huang C,Wang Y,Li X,Ren L,Zhao J,Hu Y .2020 .Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395 : 497-506.
Mazaheri T,Ranasinghe R,Al-Hasani W. .2022 .A cytokine panel and procalcitonin in COVID-19, a comparison between intensive care and non-intensive care patients. PLoS One, 17(5) : e0266652.
Lippi G,Cervellin G .2018 .Procalcitonin for diagnosing and monitoring bacterial infections: for or against?. Clin Chem Lab Med, 56 : 1193-5.
Cowman K,Rossi J,Gendlina I. Elucidating .2022 .the role of procalcitonin as a biomarker in hospitalized COVID-19 patients. Diagn Microbiol Infect Dis, 103(4) : 115721.
van Berkel M,Kox M,Frenzel T,Pickkers P,Schouten J .2020 .Biomarkers for antimicrobial stewardship: a reappraisal in COVID-. times? Crit Care, 24(1) : 600.
López-Ayala P,Alcaraz-Serna A,Valls Carbó A .2022 .Procalcitonin concentration in the emergency department predicts 30-day mortality in COVID-19 better than the lymphocyte count, the neutrophil-tolymphocyte ratio, or the C-reactive protein level. Procalcitonina es superior a recuentolinfocitario, índiceneutrófilo/linfocito y proteína C reactiva para la predicción de mortalidad a 30 días de pacientes con COVID-. Emergencias, 34 : 119-127.